Editorial: ECJ ruling a blow for advertising regulations but safeguards MS autonomy
This article was originally published in Scrip
Public health authorities now have the green light to offer financial incentives to doctors for prescribing lower-cost drugs, thanks to a European Court of Justice ruling on EU advertising legislation. This seems rather bizarre given that the same legislation stops industry, and other third parties, from doing just that.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.